![]() |
Pediatric Hypertension...
August 1, 2014 - Clinical , Featured By: Anthony Botte and Tyler Valente, PharmD Candidates c/o 2016 – Diseases which are prevalent within the pediatric population require distinct protocols for treatment accompanied by the utmost care and precision. Pediatric hypertension (HTN) is one disease state in particular that has come to the forefront of medical practice in the United States over the… |
![]() |
Quantifying the Benefits of Pharmacist Prescribing Powe...
July 1, 2014 - Featured , Professional Advice / Opinions By Davidta Brown, Senior Staff Editor – The idea of granting pharmacists the right to prescribe, as well as to counsel and dispense, has long been a source of controversy among healthcare professionals. A study out of the University of Alberta in Canada, published online in mid-April, provided some much needed concrete data for an… |
![]() |
FDA Approves Drug Elosulfase Alfa (Vimizim™) for Muco...
May 1, 2014 - Featured , In the News / Politics By: Erica Dimitropoulos Co-Copy Editor [Content- Focused] – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development… |
![]() |
The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
The Importance of Organ Donation: Perspectives and the ...
March 1, 2014 - Featured , Professional Advice / Opinions By: James Schurr, PharmD Candidate c/o 2014 and Jennifer Miao, PharmD Candidate c/o 2014 With very special thanks to Jessica Melore and Jennifer McDermott, PharmD, BCPS of NewYork-Presbyterian Hospital – Jessica Melore was 16 years old, a senior in high school, and co-captain of the tennis team when her life took a drastic turn. While… |
![]() |
A Brave New World for Lipid Management...
March 1, 2014 - Featured , In the News / Politics By: Amrita Singh, PharmD Candidate c/o 2015 – Last November, the American College of Cardiology and the American Heart Association released new lipid guidelines, which will transform the way we manage our patients with hyperlipidemia. Earlier, lipid management was based on the ATP-III guidelines, which emphasized the use of several lipid-lowering medications to reach target… |
![]() |
Going International...
March 1, 2014 - Events By: Hayeon Na, Co-Copy Editor (Content-focused) – On Tuesday, February 4th, the New Jersey Pharmacist Association (NJPhA) and Dr. Maria Leibfried hosted a seminar for international pharmacy students at St. John’s University. The seminar was held to provide information to international students, especially for those who are here as F-1 students, about their options when… |
![]() |
Say Hello to JNC8: New Hypertension Guidelines...
January 1, 2014 - Featured , In the News / Politics By: Frances Trosa PharmD Candidate c/o 2015 – After much anticipation, the report from the Eighth Joint National Committee (JNC 8) has arrived! Panel members appointed to the committee have created evidence – based recommendations to assist physicians in managing hypertensive patients. A major difference between the JNC 7 report and the JNC 8 report… |
![]() |
The Blunt Truth...
January 1, 2014 - Featured , In the News / Politics By: Katharine Cimmino, Editor-in-Chief – Marijuana, also known as “grass,” “pot,” “joint,” “weed,” “reefer,” “hashish,” and “Mary Jane,” is a very popular illicit drug.1 According to the National Survey on Drug Use and Health, “In 2012, 5.4 million persons aged 12 or older used marijuana on a daily or almost daily basis in the past 12… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
![]() |
Hope For Children with Acute Lymphoblastic Leukemia...
October 1, 2013 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Emily Whitehead, a 7-year-old girl who fought off relapsing acute lymphoblastic leukemia (ALL), has captured the hearts and prayers of the masses. Her story is an inspiration to those battling any disease with a poor prognosis and particularly holds promise for the 15% of children with ALL resistant to… |
![]() |
Meet the Dean: Interview with Dean DiGate...
October 1, 2013 - Featured , Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief and Erica Dimitropoulos, Senior Staff Editor – Just last month, St. John’s University College of Pharmacy and Health Sciences kindly welcomed a new Dean into our family, Dean Russell J. DiGate. Dean DiGate is a highly experienced educator and academic leader. He attended the University of Rochester, where… |
![]() |
FDA’s New Warning: Acetaminophen Associated with Seri...
September 1, 2013 - Featured , In the News / Politics By: Andy Zhang, PharmD Candidate c/o 2015 – On August 1st, 2013, the U.S. Food and Drug Administration (FDA) released a new warning of serious acetaminophen associated skin reactions, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP).1 Acetaminophen is one of the most widely used over-the-counter (OTC) medication, and… |
![]() |
Olmesartan Medoxomil Label Revision...
September 1, 2013 - In the News / Politics By: David Ong, PharmD Candidate c/o 2014 – Manipulating the renin-angiotensin system is one of the many ways drugs are used to treat hypertension. By blocking key steps in the renin-angiotensin cascade, blood pressure decrease may be achieved. Angiotensin II receptor blockers (ARBs) represent one of the drug classes that utilize the aforementioned mechanism. ARBs… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Purple Glove Syndrome...
May 1, 2013 - Clinical , Featured By: Sharon Janak, PharmD Candidate c/o 2013 – How can we distinguish between vascular injury and Purple Glove Syndrome (an adverse effect of phenytoin)? What are the warning signs and symptoms? Phenytoin is an anticonvulsant used to treat generalized tonic-clonic and partial seizures. It stabilizes neuronal cell membranes of the motor cortex by facilitating the… |
![]() |
AUVI-Q™: The Newest Epinephrine Device to Hit the Mar...
May 1, 2013 - In the News / Politics By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Most of us who work in a community pharmacy setting will usually get a few scripts a month for an Epi-pen™. An Epi-pen™ is a device that autoinjects epinephrine (also known as adrenaline) into a patient who is experiencing anaphylaxis. Anaphylaxis is a severe, whole-body allergic… |
![]() |
A Look at Primary Medication NonAdherence and How it ca...
February 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Assistant Student Editor – Although clinical trials can affirm the efficacy and advantages of all marketed medications, it is obvious that patients cannot benefit from a drug that they choose not to take. Therefore, promoting medication adherence is one of the easiest and most affordable ways to improve treatment outcomes. In order… |
![]() |
Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured By: Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for… |
![]() |
Safety and Efficacy of Atropine for Salivary Hypersecre...
November 1, 2012 - Clinical By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2 Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2 It also has functions in the central nervous system (CNS); it could stimulate or… |
![]() |
Mechanisms of NSAID Induced Functional Renal Toxicity...
November 1, 2012 - Clinical , Featured By: James W. Schurr & Stephen Argiro, PharmD Candidates c/o 2014 – Patients frequently utilize non-steroidal anti-inflammatory drugs (NSAIDs) for a wide variety of conditions, including but not limited to arthritis, headaches, and generalized pain. Despite an excellent safety profile, NSAIDs are associated with certain toxicities, including renal complications (particularly among at risk populations).1 Acute… |
![]() |
My Experiences at NewYork-Presbyterian Hospital...
October 1, 2012 - Professional Advice / Opinions By: Addolorata Ciccone, Student Copy Editor – As a fifth-year pharmacy student researching and ranking advanced pharmacy practice experience (APPE) sites, I felt excited at the prospect of taking the knowledge and skills I obtained in the classroom and applying it to real world patients and scenarios. My years of work in community pharmacies were… |
![]() |
A Cherokee Experience: The Story of My Ambulatory Care ...
September 1, 2012 - Professional Advice / Opinions By: Nandini Puranprashad, Pharm D. Candidate c/o 2013 – I’m sitting in a quaint coffee shop in Cherokee, North Carolina, sipping a dirty chai tea with some of my roommates with 1970s music chiming in the background as I write this article and words cannot describe my experiences at this rotation. The most surprising aspect… |
![]() |
Quick Update: Triptan Pharmacology...
August 1, 2012 - Clinical By: Neal Shah, Co-Editor-In-Chief – Migraines can be “classic” or “common.” While all migraines feature unilateral, pulsating headaches, classic migraines feature an “aura” upon onset (whereas common migraines do not). Pharmacologic treatment of migraines generally includes serotonin agonists (triptans).1 Triptans are selective agonists of the 5-hydroxytryptamine 1B and 1D (5HT1B/1D) subtypes. By activating these receptors,… |
![]() |
Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug. First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing… |
![]() |
Matching Challenge: Over-the-Counter Products...
July 1, 2012 - Puzzles By Mohamed Dungersi, Associate Student Editor – Match the following herbal products with their natural source and reason for use: A. This product is a source of omega-3 fatty acids, primarily docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). It is used to lower triglyceride levels, to lower high blood pressure, and for a variety of… |
![]() |
Student Pharmacist Star of the Month: Albana Alili...
June 1, 2012 - Professional Advice / Opinions By: Marie Huang – Each month, the Rho Chi Post has the wonderful opportunity to sit down with an inspiring leader among the student pharmacists here at St. John’s University College of Pharmacy and Health Sciences – someone who is not afraid to stand apart from the crowd and can be the change he… |
![]() |
Naloxone Distribution Programs...
June 1, 2012 - Clinical , Featured , In the News / Politics By: Mahdieh Danesh Yazdi, Associate Student Editor, with Special Thanks to Dr. Tomasz Jodlowski for his contributions to this article – In the 1990s, major urban and rural areas across the United States grappled with a common problem: drug addiction. At that time, the drugs of choice were illicit substances (i.e. heroin). In order to combat… |
![]() |
Role of Calcium Channel Blockers and Beta Blockers in C...
May 1, 2012 - Clinical , Featured By: Lunbao Huang Pharm D. Candidate c/o 2013 – The seventh report of the Joint National Committee on high blood pressure (JNC-7) states that most classes of antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers (BBs), diuretics, and aldosterone-receptor antagonists can be used for hypertensive heart failure patients except… |
![]() |
Sativex®: A Realistic Option for Advanced Cancer Pain?...
April 1, 2012 - Clinical , Featured , In the News / Politics By: Kathlynn Ferrer, Pharm.D. Candidate c/o 2013 – Nabiximols (Sativex®) is a buccal spray that has been approved for use in the UK, Spain, Germany, Denmark, New Zealand, and Canada. The active ingredients in this product are Tetrahydrocannabinol and Cannabidiol, two kinds of cannabinoids1. Cannabinoids are chemical compounds that stimulate cannabinoid receptors and are the… |
![]() |
The Diagnosis and Management of Bipolar Disorder in Chi...
March 1, 2012 - Clinical By: Marie Huang – The amphitheater at Nassau University Medical Center fills up slowly as Dr. Alan Jay Cohen, a psychiatrist from Oakland, California, makes his way up to the podium to lead a talk about bipolar disorder, specifically differentiating between its presentations in adults versus in developing children. Among nonprofessionals, bipolar disorder is simply… |
![]() |
Pharmacists in Alberta Allowed to Renew Prescriptions...
March 1, 2012 - In the News / Politics By: Mohamed Dungersi – Starting July 1, 2012, Albertans will be able to have their prescriptions renewed at their local pharmacies and pharmacists will receive reimbursements for the service. Patients will be able to renew medications for blood pressure, birth control, and asthma (particularly, inhalers) without waiting weeks to get into their family doctor’s office.… |
![]() |
CHF, a Rare but Serious Presentation of Graves’ disea...
March 1, 2012 - Clinical , Featured By: James Schurr, Pharm.D. Candidate c/o 2014 – Graves’ disease is an autoimmune disorder that results in a state of thyrotoxicosis, or a cause of hyperthyroidism, due to the Immunoglobulin G-mediated agonism of thyroid stimulating hormone (TSH) receptors located on the thyroid. Stimulation of TSH receptors causes an increase in circulating thyroxine (T4) and triiodothyronine… |
![]() |
FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans. Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack. On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for… |
![]() |
Clevidipine in the Management of Hypertensive Emergency...
January 1, 2012 - Clinical , Featured By: Neal Shah – Defined by the Joint National Committee, hypertension (HTN) is a systolic blood pressure (SBP) greater than or equal to 140 mmHg and a diastolic blood pressure (DBP) greater than or equal to 90 mmHg. Patients with Stage 1 HTN have a SBP between 140 and 159 mmHg and DBP between 90… |